Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v3.8.0.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation

Note 6 – Stock-based compensation

 

The Company recorded approximately $105,000 and $212,000 of stock-based compensation related to employee stock options for the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018, there was $441,000 of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company’s operating expenses over a weighted average period of 1.0 year.

 

As of March 31, 2018, an aggregate of 2,239,000 shares of common stock were reserved for issuance under the Company’s Equity Incentive Plans, including 426,000 shares subject to outstanding common stock options granted under the plan and 1,813,000 shares available for future grants. The administrator of the plan determines the times when an option may become exercisable at the time of grant. Vesting periods of options granted to date have not exceeded five years. The options generally will expire, unless previously exercised, no later than ten years from the grant date. The Company is using unissued shares for all shares issued for options and restricted share awards.

 

The following schedule presents activity in the Company’s outstanding stock options for the three months ended March 31, 2018 (in thousands, except per share amounts):

 

    Number of Shares available for Grant     Total Options Outstanding     Weighted Average Exercise Price     Aggregate Intrinsic Value  
Balance at December 31, 2017     1,656       711     $ 8.39     $ 1,640  
Exercised     -       (128 )     1.45       -  
Granted     -       -       -       -  
Cancelled     157       (157 )     3.01       -  
Balance at March 31, 2018     1,813       426     $ 12.44     $ 1,192  

 

As of March 31, 2018, options to purchase 425,637 shares of common stock, with an aggregate intrinsic value of $569,000, were outstanding that were fully vested or expected to vest with a weighted average remaining contractual term of 3.0 years. As of March 31, 2018, options to purchase 396,472 shares of common stock, with an intrinsic value of $569,000 were exercisable with a weighted average exercise price of $10.78 per share and a weighted average remaining contractual term of 2.7 years. The aggregate intrinsic value of outstanding and exercisable options at March 31, 2018 was calculated based on the closing price of the Company’s common stock as reported on the NASDAQ markets on March 31, 2018 of $5.95 per share less the exercise price of the options. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company’s common stock and the exercise price of the underlying options.